| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6061956 | Annals of Allergy, Asthma & Immunology | 2015 | 4 Pages |
Abstract
This study from the United States suggests that omalizumab is effective and safe in patients with refractory CU who use omalizumab for longer than 1 year. Periodic attempts at weaning patients with CU from omalizumab should be attempted because there could be a chance of spontaneous remission. This might be difficult because symptoms are likely to recur, but restarting omalizumab in these patients seems effective and safe.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Daniel MD, Saurin MD, David A. MD,